Kohjin Bio Co

Kohjin Bio Co P/B

The P/B (Price-to-Book Ratio) of Kohjin Bio Co (177A.T) as of Nov 3, 2026 is 1.06. In the previous year, P/B (Price-to-Book Ratio) was 1.84 — a change of -42.19% (lower).

P/B

1.06

YoY

-42.19%

Last updated:

P/B (Price-to-Book Ratio) of Kohjin Bio Co is 2025 1.06 . P/B (Price-to-Book Ratio) of Kohjin Bio Co was 2024 1.84 . It decreases by -42.19% lower compared to the previous year.

The Kohjin Bio Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2022
2.77 JPY
Jan 1, 2023
2.03 JPY
Jan 1, 2024
1.84 JPY
Jan 1, 2025
1.06 JPY
The Kohjin Bio Co P/B history
YEARP/BYoY
1.06-42.19%
1.84-9.71%
2.03-26.54%
2.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kohjin Bio Co Stock analysis

What does Kohjin Bio Co do? Kohjin Bio Co Ltd generates revenue through three business segments. The Tissue Culture segment sells serum-free media for regenerative medicine and immunotherapy research, targeting research institutions and biotech companies. The Microbiology segment offers pathogen testing media for clinical, food, and pharmaceutical quality control, purchased by hospitals, food producers, and cosmetics manufacturers. The Cell Processing segment provides contract cell processing services to medical institutions under the Regenerative Medicine Safety Act, with facilities approved for manufacturing specified cell products. Revenue comes from direct sales of media products and service contracts for cell processing operations. The company's products include bacterial testing media, in vitro diagnostic drugs, and cell culture media, all sold under its own brand. Medical institutions, research organizations, and quality control departments in food and pharmaceutical industries are the primary buyers. The Microbiology segment serves clinical laboratories and food safety testing facilities, while the Tissue Culture segment caters to regenerative medicine research centers. Cell Processing services are contracted by hospitals and clinics requiring specialized cell manufacturing under regulatory compliance. Kohjin Bio's business model relies on selling specialized media for laboratory and medical applications, with recurring revenue from long-term contracts in cell processing. The Microbiology segment's products are used in routine pathogen testing, ensuring steady demand from healthcare and food sectors. The Tissue Culture segment's serum-free media support emerging therapies, attracting biotech firms seeking advanced research tools. Cell Processing services are driven by Japan's expanding regenerative medicine market, where medical institutions outsource cell manufacturing to compliant facilities. Kohjin Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kohjin Bio Co stock

P/B (Price-to-Book Ratio) of Kohjin Bio Co is 1.06 in 2025.

P/B (Price-to-Book Ratio) of Kohjin Bio Co changed from 1.84 to 1.06, representing a -42.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Kohjin Bio Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Kohjin Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Kohjin Bio Co

All Key Metrics — Kohjin Bio Co